13417
Blog

The Hidden Costs of Clinical AI Marketplaces

The term “AI marketplace” gets thrown around a lot, but it rarely means the same thing twice. In fact, there are several flavors of marketplaces in healthcare today, and each comes with different promises, architectures and limitations. If you’re evaluating options, it’s critical to understand the tradeoffs. Because when it comes to clinical AI, the wrong model — or the wrong choice — can stall your strategy before it even starts.

Marketplace Type 1: Aggregators

These marketplaces focus on volume. They pull together dozens of third-party algorithms under one commercial umbrella. On the surface, the pitch is appealing: more choice, more flexibility and faster access to innovation.

But here’s the issue: These vendors don’t run the AI themselves. Each algorithm comes with its own integration path, its own support model and its own way of consuming and outputting data. That burden falls on your team.

Validation becomes a second challenge. Without performance oversight — especially on your own population data — every deployment becomes a guess. One that could carry clinical or legal risk.

Even if you clear those hurdles, the bigger problem is impact. Without shared infrastructure or orchestration, aggregators turn every new use case into a net-new IT project. There’s no workflow consistency across solutions, and no way to link them across care settings. 

That matters because delivering real impact in a single disease state often requires a combination of capabilities: radiology AI for detection and triage, care coordination for timely intervention and patient management to ensure follow-up and treatment.

Marketplaces can’t support that kind of connected experience. You’re left with fragmented tools that solve for one moment in time — not the full patient journey.

Marketplace Type 2: PACS-Native

This model is embedded within existing PACS environments, offering radiologists access to AI tools from inside their native workspace. On paper, it seems efficient, but there are tradeoffs here, too.

PACS companies aren’t AI companies. They don’t specialize in building infrastructure to support AI. They surface results, but they don’t orchestrate them. They typically don’t handle data normalization, logic routing or real-time monitoring. 

If you’re a health system that doesn’t store certain studies in PACS, or you’re looking to extend AI into the Emergency Department (ED), cardiology or inpatient care, this model quickly hits its limits with workflow integration. 

What’s missing is the intelligence layer between the scan and the action.

What These Marketplaces All Miss

No matter how they’re packaged, most marketplaces are missing the same foundational elements. They focus on content, but lack the infrastructure needed to:

  • Ingest and normalize clinical data
  • Apply logic to run the right algorithm at the right time
  • Deliver results through a unified workflow — linking radiology, care coordination and patient management
  • Measure AI performance, user adoption and clinical impact

Without those layers, even the best algorithm ends up as another disconnected output, and health systems could stall AI strategy after one or two deployments.

Questions to Ask a Vendor Before You Commit

If you’re evaluating a marketplace, don’t just ask how many algorithms are in the catalog. Ask:

  • How many are actually live and used across departments?
  • Who owns the integration and orchestration?
  • Can we track usage, outcomes and clinical value?
  • Will our teams be working across multiple interfaces and contracts, or a unified system?

These aren’t just implementation details. They’re what determine whether you’ll still be using the solution two years from now. If a vendor can’t answer these, they’re not ready to support enterprise-scale AI.

Explore the Latest AI Insights, Trends and Research

Headshot of Reut Yalon
Reut Yalon, PhD
Reut Yalon, PhD, is the Chief Product Officer at Aidoc, leading Aidoc’s product group and the company’s product strategy. Since joining Aidoc, Dr. Yalon and her team developed and commercialized dozens of clinical, FDA-cleared products that are widely used daily in healthcare centers around the world, based on a market-leading overarching framework that enables rapid deployment of new products to the market. Prior to joining Aidoc, she held product positions in medical imaging start-ups, with a passion to build products from ideation to commercialization. Dr. Yalon received her post-doctorate and PhD from the Weizmann Institute of Science, where she developed novel imaging methods for non-invasive prenatal clinical applications. A prolific scientist, Dr. Yalon authored over 10 scientific papers and two book chapters.
Reut Yalon, PhD
Chief Product Officer